S-1/A: Helius Medical Technologies Announces Proposed Public Offering of Common Stock and Warrants

Helius Medical Technologies is seeking to raise capital through a best efforts public offering of common stock, pre-funded warrants, and accompanying warrants.

Summary

• Helius Medical Technologies has filed an amendment to its S-1 registration statement for a proposed best efforts public offering.
• The offering includes shares of Class A common stock, Series A warrants, Series B warrants, and pre-funded warrants to purchase common stock.
• Up to 1,801,801 shares of common stock are being offered, along with warrants to purchase a matching number of shares.
• The assumed combined public offering price is $4.44 per share and accompanying warrants.
• Series A warrants are exercisable at 110% of the offering price and expire in five years, while Series B warrants are exercisable at 100% of the offering price and expire in twelve months.
• Pre-funded warrants are offered to purchasers who would otherwise exceed beneficial ownership limits.
• Craig-Hallum Capital Group LLC is acting as the exclusive placement agent for the offering.
• The company intends to use the net proceeds from this offering for funding operations, working capital and general corporate purposes.
• The company estimates net proceeds of approximately $7.1 million from the offering, after deducting placement agent fees and estimated offering expenses.

Sentiment

Score: 4

Explanation: The document outlines a capital raise attempt by a company facing financial difficulties and Nasdaq compliance issues. While the capital raise itself could be seen as a positive step towards addressing these issues, the underlying financial instability and regulatory concerns contribute to a negative sentiment.

Positives

• The offering provides Helius Medical Technologies with additional capital to fund operations and working capital.
• The company has the flexibility to offer pre-funded warrants to certain investors.
• The company has partnered with Lovell Government Services to make the PoNS device available to federal healthcare systems.

Negatives

• The company has a history of losses and may not achieve or sustain profitability in the future.
• The company received a Nasdaq deficiency notice for not meeting the minimum stockholders' equity requirement.
• The company's independent registered public accounting firm has included an explanatory paragraph relating to the company's ability to continue as a going concern in its report on the audited financial statements.
• The company may not sell all or any of the securities offered hereby.
• The company is not in compliance with Nasdaqs continued listing requirements.
• The company has not paid and does not intend to pay dividends on its Common Stock.

Risks

• The company may not raise the amount of capital it believes is required for its business plans.
• The market price of the company's common stock may be highly volatile.
• The company is not in compliance with Nasdaq's continued listing requirements.
• The company's inability to protect its confidential information and trade secrets would harm its business and competitive position.
• The company's failure to comply with healthcare laws could result in substantial penalties and financial exposure.
• The company is reliant on third-party, single-sourced contract manufacturing, exposing it to risks that could delay sales or result in higher costs or lost product revenues.

Future Outlook

The company expects expenses to increase as it continues to conduct trials of PoNS Therapy and pursues further regulatory approvals.

Industry Context

The neuromodulation market is new and uncertain, and market awareness of the PoNS device is limited.

Stakeholder Impact

• Shareholders may experience dilution as a result of the offering.
• The company's ability to continue as a going concern is uncertain, which could impact stakeholders.

Next Steps

• The company intends to timely submit a plan to Nasdaq to regain compliance.
• The company will continue to conduct trials of PoNS Therapy and pursue further regulatory approvals.

Key Dates

Keywords

Helius Medical Technologies, public offering, common stock, warrants, pre-funded warrants, PoNS, neuromodulation, Craig-Hallum, capital raise, HSDT